The Zhitong Finance App learned that LLY.US (LLY.US) announced on Monday that Foundayo, an oral weight loss medication taken once a day, significantly reduced the severity of obstructive sleep apnea (OSA) in obese patients in late-stage clinical trials. Eli Lilly plans to submit an application to the US Food and Drug Administration (FDA) before the end of this year to seek approval for Foundayo's use in the treatment of moderate to severe obstructive sleep apnea in obese or overweight adult patients. As of press release, Eli Lilly's stock price had risen more than 3.4% to $1399.81.

The Zhitong Finance App learned that LLY.US (LLY.US) announced on Monday that Foundayo, an oral weight loss medication taken once a day, significantly reduced the severity of obstructive sleep apnea (OSA) in obese patients in late-stage clinical trials. Eli Lilly plans to submit an application to the US Food and Drug Administration (FDA) before the end of this year to seek approval for Foundayo's use in the treatment of moderate to severe obstructive sleep apnea in obese or overweight adult patients. As of press release, Eli Lilly's stock price had risen more than 3.4% to $1399.81.